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Background
Cross-sectional study, in which were evaluated the bone
mineral density of 53 patients from the Rheumatology
ambulatory, diagnosed with JSLE in their childhood or
teenage years, according to American College of Rheu-
matology criteria.
Aim
Evaluate the bone mass in a group of patients diagnosed
with juvenile systemic lupus erythematosus (JSLE),
which carry high risks of developing low bone mass, as
well as verifying alterations on calcium metabolism.
Method
Cross-sectional study, in which were evaluated 53
patients from the Rheumatology ambulatory in HUCFF/
UFRJ, diagnosed with JSLE in their childhood or teenage
years, according to ACR (American College of Rheuma-
tology) criteria. Subjects were submitted to a single
blood and urine collection for dosing of the following
variables: alkaline phosphatase, serum phosphorus and
calcium, urea, creatinine, erythrocyte sedimentation rate
(ESR), intact PTH, free T4, TSH, 24-hour calciuria.
Bone density was measured from lumbar spine, and full
body and/or total femur, according to age range, using
DEXA methods and Prodigy Advance equipment. Also,
medical records were analyzed collecting the following
data: age, sex, time coping with the disease, body mass
index (BMI), disease progression with SLEDAI average
for the last 6 months, number of diagnostic criteria,
cumulative dose of 3 drug-induced osteoporosis classes
(glucocorticoid, methotrexate and anticoagulant). Finally,
the collected data was submitted to statistic analysis.
Patients suffering from renal insufficiency or currently
on bone antiresorptive or bone formation stimulators
drugs were excluded.
Results
92% of patients were females, being only 4 male sub-
jects. Analyzed parameters averages, and their corre-
sponding standard deviation (SD): Age – 21 years old
(4,0); time coping with the disease – 7,9 years (5,7);
number of ACR criteria at diagnosing moment – 5,6
(1,4); BMI – 23,2 kg/m
2 (4,7); SLEDAI – 3,7 (4,6)
R=1,23. Not only was the accumulative glucocorticoid
dosage calculated, but also the prednisone equivalency.
The maximum used dosage was 133,88g, with an aver-
age of 29,1g and standard deviation of 27,8 (R=1,0). The
only anticoagulant used was warfarin, with maximum
dosage of 39,76g, average of 1,3g and standard deviation
of 5,9 (R=4,5). Maximum dosage for methotrexate was
2,49g, average of 0,2g and standard deviation of 0,6
(R=2,6). 15 patients presented densitometry alterations,
characterized by Z-score lower or equal to 2 standard
deviation. No clinically significant laboratorial alterations
on calcium metabolism were found.
Conclusion
No direct or inverse linear relation (correlation) was
observed between the analyzed parameters and densito-
metry findings according to the Z-score.
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